BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

...on bispecifics targeting PSMA (No. 340) and STEAP1...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

...Phase Ib data for AK104 from Akeso Inc. (HKEX:9926). AMG509 is a bispecific mAb targeting STEAP1...
...OX40L (CD134L) - OX40 ligand PD-1 (PDCD1; CD279) - Programmed cell death 1 STEAP1 - Six-transmembrane epithelial antigen of prostate 1 Stephen...
BioCentury | Jun 3, 2013
Clinical News

DSTP3086S: Phase I data

...composed of a humanized IgG1 mAb against six-transmembrane epithelial antigen of the prostate 1 ( STEAP1...
BioCentury | Jan 7, 2002
Clinical News

Compounds targeting STEAP-1 ion channel or BPC-1 secreted protein regulatory update

Agensys received U.S. Patents Nos. 6,329,503 and 6,277,972. The ‘503 patent covers STEAP-1, which is a cell surface ion channel overexpressed in prostate cancer patients. Patent ‘972 covers BPC-1 and methods for producing the protein....
BioCentury | Feb 28, 2000
Emerging Company Profile

UroGenesys: Racing through prostate proteins

UroGenesys Inc. has developed a platform focused on finding proteins involved in urological diseases as fast as possible. In two years of work, the company has identified 40 proteins that meet strict criteria for differential...
BioCentury | Dec 13, 1999
Company News

UroGenesys other research news

UroGenesys researchers published in the Proceedings of the National Academy of Sciences the identification of STEAP as a protein expressed predominantly in human prostate tissue that is upregulated in multiple cancer cell lines. They suggested...
Items per page:
1 - 6 of 6